Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Acute myeloid leukaemia in children, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
A third of children relapse and only half of those are cured.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Infant AML with NUP98 or CBFA2T3::GLIS2 fusions has no effective therapy.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Targets · KRAS roadmap.
Anthracycline cardiotoxicity and infection deaths from the most intensive chemotherapy given to children.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
CR+CRh 22.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Bortezomib added to chemotherapy did not improve three-year event-free survival (44.
A milestone in how this cancer is treated.